Publisher
Springer Science and Business Media LLC
Reference53 articles.
1. Gu Z, Wang L, Yao X, Long Q, Lee K, Li J, et al. ClC-3/SGK1 regulatory axis enhances the olaparib-induced antitumor effect in human stomach adenocarcinoma. Cell Death Dis. 2020;11:898.
2. Venerito M, Vasapolli R, Rokkas T, Malfertheiner P. Gastric cancer: epidemiology, prevention, and therapy. Helicobacter. 2018;23(Suppl 1):e12518.
3. Thrift AP, El-Serag HB. Burden of gastric cancer. Clin Gastroenterol Hepatol. 2020;18:534–42.
4. Kawada J, Mizuno M, Fukada A, Nakano M, Murotani M, Nagano S, et al. Analysis of chemotherapy-induced nausea and vomiting during chemotherapy for gastric cancer. Gan To Kagaku Ryoho Cancer Chemother. 2022;49:462–4.
5. Wang BC, Zhang ZJ, Fu C, Wang C. Efficacy and safety of anti-PD-1/PD-L1 agents vs chemotherapy in patients with gastric or gastroesophageal junction cancer: a systematic review and meta-analysis. Medicine. 2019;98:e18054.